43 0 2

Partnering

MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.

Learn more

Company Highlights

  • Robust pipeline in oncology, autoimmunity and infectious diseases
  • Partners include Boehringer Ingelheim, Pfizer and Servier
  • Fully-integrated biologics capabilities across product development process 
  • Strong financial position and blue-chip investor base
  • Experienced management team and highly collaborative corporate culture 
Learn more

Overview

Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.

Learn more

In the News

2008 News Archive

September 26, 2008 | BioWorld Today
MacroGenics Raises $25M To Boost Stem Cell Line

September 26, 2008 | Washington Business Journal
New Venture Round Gives MacroGenics $25M Boost

September 25, 2008 | The Washington Post
Biotech Raises $25 Million In Financing

August 25, 2008 | BioWorld Today
86 Years After Insulin, Type I Diabetes Drugs Promise More

July 18, 2008 | The Washington Post
MacroGenics Buys Drug Developer To Bolster Cancer Work

July 17, 2008 | BioWorld Today
MacroGenics Boosts Anticancer Pipeline With Raven Acquisition

July 17, 2008 | Washington Business Journal
MacroGenics Buys California-Based Raven Biotechnologies

January 17, 2008 | Forbes
Delaying Diabetes

News Archive: 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All